Topo II Inhibitor Sensitivity: TOP2A
Naniwa, J., J. Kigawa, et al. (2007). "Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer." Int J Gynecol Cancer 17(1): 76-82.
Koshiyama, M., H. Fujii, et al. (2001). "Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas." Anticancer Res 21(4B): 2925-2932.
Topo II Inhibitor Resistance: PGP
Baekelandt, M. M., R. Holm, et al. (2000). "P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer." Anticancer Res 20(2B): 1061-1067.
Holzmayer, T. A., S. Hilsenbeck, et al. (1992). "Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas." J Natl Cancer Inst 84(19): 1486-1491.